RCS - Oxford Biomedica PLC - Credit Suisse's Global Healthcare Conference <Origin Href="QuoteRef">OXB.L</Origin>

Oxford BioMedicaAnnouncement

03/03/2015 07:12

RNS Number : 2693G
Oxford Biomedica PLC
03 March 2015
Oxford BioMedica to Participate in Credit Suisse's Global Healthcare One-on-One Conference 
London, UK - 3 March 2015: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE:OXB), a leading gene and cell therapy company, announces that John Dawson, Chief Executive Officer, and Tim Watts, Chief Financial Officer, will participate in the Credit Suisse Global Healthcare One-on-One Conference on 3 March 2015, in London. 
The conference is predominantly one-on-one meetings between investors and senior management teams from more than 50 global healthcare companies. The conference is open to companies by invitation only.
- Ends -
For further information, please contact:
Oxford BioMedica plc:
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Tel: +44 (0)1865 783 000
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton
Tel: +44 (0)20 3709 5700
Notes for editors
About Oxford BioMedica
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy company with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Company's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Company has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk .

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NRALLFISVVIFIIE